Use of maribavir in treatment regimens

A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising administering maribavir in an amount of 1200 mg orally twice daily,

• wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant and an immunosuppressant,
• wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant and the immunosuppressant,
• wherein the method comprises monitoring immunosuppressant drug levels throughout treatment with maribavir, and optionally adjusting the dose of the immunosuppressant,
• wherein the patient is an adult, or a child of 12 years of age or older and weighing at least 35 kg, and wherein the patient is refractory to treatment with one or more of ganciclovir, valganciclovir, cidofovir, or foscarnet.

A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising administering maribavir in an amount of 800 mg orally twice daily,

• wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant and an immunosuppressant,
• wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant and the immunosuppressant,
• wherein the method comprises monitoring immunosuppressant drug levels throughout treatment with maribavir, and optionally adjusting the dose of the immunosuppressant,
• wherein the patient is an adult or a child of 12 years of age or older, and wherein the patient weighs at least 35 kg, wherein the patient is refractory to treatment with one or more of ganciclovir, valganciclovir, cidofovir, or foscarnet.